Medical Devices APAC

APAC Alzheimer's Blood Tests Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC Alzheimer's Blood Tests Market Industry Trends and Forecast to 2034: Segmented by (Biomarker, Use, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $70.3 Mn Placeholder estimate
Estimate 2025 $88.7 Mn 18.9% of the global market
Projected 2034 $720.3 Mn 712% Adds $631.6 Mn over 9 forecast years
CAGR 2025–2034 26.2% Faster than 98% of 193 Medical Devices markets here
Key players 5
  • APAC is 18.92% of the global market.
  • Among regions, the largest is North America at $234.9 Mn.
  • Fastest growing: Middle East at 26.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$631.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Alzheimer's Blood Tests Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $70.3 Mn — —
2025 (base) $88.7 Mn +$18.4 Mn —
2026 (forecast) $112.0 Mn +$23.2 Mn +26.2%
2027 (forecast) $141.3 Mn +$29.3 Mn +59.3%
2028 (forecast) $178.3 Mn +$37.0 Mn +101%
2029 (forecast) $225.0 Mn +$46.7 Mn +153.7%
2030 (forecast) $284.0 Mn +$59.0 Mn +220.1%
2031 (forecast) $358.4 Mn +$74.4 Mn +304%
2032 (forecast) $452.3 Mn +$93.9 Mn +409.8%
2033 (forecast) $570.8 Mn +$118.5 Mn +543.4%
2034 (forecast) $720.3 Mn +$149.5 Mn +712%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC Alzheimer's Blood Tests Market Analysis at a glance
Market size, 2025$88.7 Mn placeholder estimate
Forecast, 2034$720.3 Mn placeholder estimate
Growth (CAGR), 2025–203426.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
Also calledBlood-Based Biomarkers for Alzheimer's Disease
SegmentsBiomarker, use and end user (see all)
Key playersC2N Diagnostics, Roche Diagnostics, Fujirebio, Quanterix, Quest Diagnostics (see all)
Active clinical trials29 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC Alzheimer's Blood Tests Market Analysis Executive Summary

Alzheimer's blood tests measure proteins such as p-tau and amyloid in blood to help diagnose Alzheimer's disease without a brain scan.

Key segments of the alzheimer's Blood Tests market include biomarker (p-Tau217, Amyloid Beta 42/40 and Neurofilament Light) and use (Diagnosis, Clinical Trial Screening and Monitoring).

Bar chart: Asia Pacific Alzheimer's Blood Tests market size, 2024–2034, placeholder estimates. $70.3 Mn in 2024, $88.7 Mn in 2025 and $720.3 Mn in 2034, 26.2% CAGR.
Asia Pacific Alzheimer's Blood Tests market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC Alzheimer's Blood Tests Market Dynamics

Market Growth Drivers

Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the alzheimer's Blood Tests market.

Opportunity

Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the alzheimer's Blood Tests market room to grow, especially in emerging markets.

Market Restraints

Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the alzheimer's Blood Tests market.

Competitive Landscape for Alzheimer's Blood Tests Market in APAC

The alzheimer's Blood Tests market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Alzheimer's Blood Tests Market in APAC

Alzheimer's Blood Tests in APAC: rules, payment and research

In some of the countries we cover here, medical devices are regulated by TGA (Australia)⁠[1], NMPA (China)⁠[2], MDACS (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], MDA (Malaysia)⁠[6], Medsafe (WAND) (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], Ministry of Health (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Ministry of Health (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28]. ClinicalTrials.gov lists 29 studies on Alzheimer's Blood Tests that are recruiting, active or about to start in APAC.⁠[29]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] Medical Device Authority. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] Ministry of Health of Indonesia. Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Ministry of Health of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

[29] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how alzheimer's Blood Tests products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Alzheimer's Blood Tests right now, from free public sources.

Clinical trials

29 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Roche 2 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Eli Lilly and Company 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Alzheimer's Blood Tests in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Alzheimer's Blood Tests market in Asia Pacific?
Placeholder estimate: about $88.7 Mn in 2025, rising to about $720.3 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Alzheimer's Blood Tests market in Asia Pacific growing?
Placeholder estimate: about 26.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Alzheimer's Blood Tests market report cover?
The report splits the market by biomarker (p-Tau217, Amyloid Beta 42/40, Neurofilament Light), use (Diagnosis, Clinical Trial Screening, Monitoring) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Alzheimer's Blood Tests market?
Key players include C2N Diagnostics, Roche Diagnostics, Fujirebio, Quanterix and Quest Diagnostics.
What is driving the Alzheimer's Blood Tests market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the alzheimer's Blood Tests market.
How many clinical trials on Alzheimer's Blood Tests are running in Asia Pacific?
29 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Alzheimer's Blood Tests?
PubMed lists 504 papers on Alzheimer's Blood Tests added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in APAC

See all

Related on diagnostics and lab testing and alzheimer's

See the topic